Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Intragrand Pharma
Suzhou, Chinaintragrandpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Intragrand Pharma is a start-up biotech company focused on novel drug discovery and development for inflammation, fibrosis, and other unmet clinical needs. Its lead program is ITG-1052 (lenamilast), an investigational inhaled PDE4 inhibitor targeting idiopathic pulmonary fibrosis and other respiratory indications. The company recently licensed this asset to Transpire Bio for all territories except China.
- Therapeutic areas
- PulmonologyImmunologyOther
- Modalities
- Small moleculeInhaled drug delivery therapy
- Industry
- Biotech
02
Partnerships
Transpire Bio Inc. – exclusive license agreement for ITG‑1052 outside China
Beyond the preview
Go deeper on Suzhou Intragrand Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Intragrand Pharma.